Systems Biology and Nanotechnology

  • Michelle S. Bradbury
  • Hedvig Hricak
  • James R. Heath


Explosive growth in the fields of molecular biology—particularly in the integrated fields of genomics, proteomics, and informatics (collectively known as systems biology)— is transforming our understanding of disease at the molecular level, and will begin transforming general medical practice within the coming decade into a medicine that is personalized, predictive, preventative, and participatory (i.e., “P4” medicine). This emerging molecular picture of disease is already driving the development of new classes of drugs that are targeted at the specific molecular errors that trigger the transformation from health to disease. As a general rule, these new drugs are effective only on patient subpopulations. This limitation is driving the integration of molecular therapeutics with in vivo and in vitro molecular diagnostics, which can be used for prescreening patients and/or for monitoring therapeutic responses. This, in turn, is driving the development of new in vitro and in vivo (molecular imaging) diagnostic technologies, with oncology turning into the proving ground for many of these new concepts.


Sentinel Lymph Node Molecular Imaging Personalized Medicine Target Probe Spin Echo 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aboagye EO, Luthra SK, Brady F, Poole K, Anderson H, Jones T, Boobis A, Burtles SS, Price P (2002) Cancer research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer 86:1052–1056Google Scholar
  2. Aebersold R, Anderson L, Caprioli R, Druker B, Hartwell L, Smith R (2005) Perspective: a program to improve protein biomarker discovery for cancer. J Proteome Res Jul-Aug; 4: 1104–1109Google Scholar
  3. Anderson SA, Wickline SA, Kotyk JJ (2000) Magnetic resonance contrast enhancement of neovasculature with ανβ3-targeted nanoparticles. Magn Res Med 44:433–439Google Scholar
  4. Anderson SA, Glod J, Arbab AS, Noel M, Ashari P, Fine HA, Frank JA (2005) Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 105:420–425PubMedGoogle Scholar
  5. Backmann N, Zahnd C, Huber F, Bietsch A, Plückthun A, Lang H-P, Güntherodt H-J, Hegner M, Gerber C (2005) A label-free immunosensor array using single chain antibody fragments. Proc Natl Acad Sci USA 102:14587–14592PubMedGoogle Scholar
  6. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ (1999) Evolution of neoplastic cell lineages in Barrett’s esophagus. Nat Genet 22:106–109PubMedGoogle Scholar
  7. Betensky RA, Louis DN, and Cairncross JG (2002) Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495–2499PubMedGoogle Scholar
  8. Brody JP, Osbom TD, Forster FK, Yager P (1996) A planar microfabricated fluid filter. Sens Actuators A Phys 54:704–708Google Scholar
  9. Bunimovich Y, Shin YS, Yeo WS, Amori M, Kwong G, Heath JR (2006) Quantitative real-time measurements of DNA hybridization with alkylated nonoxidized silicon nanowires in electrolyte solution. J Am Chem Soc 128:16323–16331PubMedGoogle Scholar
  10. Bunimovich YL, Ge G, Beverly KC, Ries RS, Hood L, Heath JR (2004) Electrochemically programmed, spatially selective biofunctionalization of silicon wires. Langmuir 20:10630–10368PubMedGoogle Scholar
  11. Chatterjee SK, Zetter BR (2005) Cancer biomarkers: knowing the present and predicting the future. Future Oncol 1:37–50PubMedGoogle Scholar
  12. Cheng MM, Cuda G, Bunimovich YL, Gaspari M, Heath JR, Hill HD, Mirkin CA, Nijdam AJ, Terracciano R, Thundat T, Ferrari M (2006) Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol 10:11–19PubMedGoogle Scholar
  13. Choi Y, Baker JR (2005) Targeting cancer cells with DNA-assembled dendrimers: a mix and match strategy for cancer. Cell Cycle 4:669–671PubMedGoogle Scholar
  14. Choudhury RP, Fuster V, Fayad ZA (2004) Molecular, cellular, and functional imaging of atherosclerosis. Nat Rev Drug Discov 3:913–925PubMedGoogle Scholar
  15. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, Be Baetselier P, Muyldermans S, Revets H (2004) Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64:2853–2857PubMedGoogle Scholar
  16. Cummins JM, VelculescuVE (2006) Implications of micro-RNA profiling for cancer diagnosis. Oncogene 25:6220–6227PubMedGoogle Scholar
  17. Dahan M, Levi S, Luccardini C, Rostaing P, Riveau B, Triller A (2003) Diffusion dynamics of glycine receptors revealed by single quantum dot tracking. Science 302:442–445PubMedGoogle Scholar
  18. Dufes C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schatzlein AG (2005) Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res 65:8079–8084PubMedGoogle Scholar
  19. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161–171PubMedGoogle Scholar
  20. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM (2001) Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaque. Circulation 104:1280–1285PubMedGoogle Scholar
  21. Fortina P, Kricka LJ, Surrey S, Grodzinski P (2005) Nanobiotechnology: the promise and reality of new approaches to molecular recognition. Trends Biotechnol 23:168–173PubMedGoogle Scholar
  22. Gao X, Yuanyuan C, Levenson RM, Chung LWK, Nie S (2004) In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotech 8:969–976Google Scholar
  23. Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S (2005) In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol16:63–72Google Scholar
  24. Goessl C (2003) Noninvasive molecular detection of cancer—the bench and the bedside. Curr Med Chem 10:691–706PubMedGoogle Scholar
  25. Grimm J, Perez JM, Josephson L, Weissleder R (2004) Novel nanosensors for rapid analysis of telomerase activity. Cancer Res 64:639–643PubMedGoogle Scholar
  26. Guller U, Nitzsche E, Moch H, Zuber M (2003) Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients? J Natl Cancer Inst 95:1040–1043PubMedGoogle Scholar
  27. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedGoogle Scholar
  28. Harisinghani MG, Barentsz J, Hahn PF et al (2003a) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 3:2491–2499Google Scholar
  29. Hayflick L (1007) Mortality and immortality at the cellular level. Biochemistry 62:639–43Google Scholar
  30. Heath JR (2007) Chap. 12. In: Mirkin C, Niemeyer CM (eds) Label-free nanowire and nanotube biomolecular sensors for in vitro diagnostics of cancer and other diseases, nanobiotechnology. Wiley, New York, p 215Google Scholar
  31. Heath JR, Phelps ME, Hood L (2003) NanoSystems biology. Mol Imaging Biol 5:312–325PubMedGoogle Scholar
  32. Hegner M, Arntz Y (2004) Advanced biosensing using micromechanical cantilever arrays. Methods Mol Biol 2004; 242:39–49Google Scholar
  33. Helms B, Meijer EW (2006) Dendrimers at work. Science 313:929–930PubMedGoogle Scholar
  34. Hernandez J, Thompson I (2004) Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 101:894–904PubMedGoogle Scholar
  35. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, Hazle JD, Halas NJ, West JL (2003a) Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA. 100:13549–13554PubMedGoogle Scholar
  36. Hirsch LR, Jackson JB, Lee A, Halas NJ, West JL (2003b) A whole blood immunoassay using gold nanoshells. Anal Chem 75:2377–2381PubMedGoogle Scholar
  37. Hood L, Perlmutter RM (2004) The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol 22:1215–1217PubMedGoogle Scholar
  38. Hood L, Heath JR, Phelps ME, Lin B (2004) Systems biology and new technologies enable predictive and preventative medicine. Science 306:640–643PubMedGoogle Scholar
  39. Hughes T, Branford S (2003) Molecular monitoring of chronic myeloid leukemia. Semin Hematol 40(Suppl 2):62–68PubMedGoogle Scholar
  40. Ichikawa T, Hoegemann D, Saeki Y, Tyminski E, Terada K, Weissleder R, Chiocca EA, Basilion JP (2002) MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia 4:523–530PubMedGoogle Scholar
  41. Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, Eng JK, Bumgarner R, Goodlett DR, Aebersold R, Hood L (2001) Integrated genomic and proteomic analyses of a systemically perturbed metabolic network. Science 292:929–934PubMedGoogle Scholar
  42. Ihre HR, Padilla De Jesus OL, Szoka FC, Frechet JM (2002) Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug Chem 13:443–452PubMedGoogle Scholar
  43. Isaacs JT (1999) The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin N Am 26:263–273Google Scholar
  44. Jaffer FA, Weissleder R (2004) Seeing within: molecular imaging of the cardiovascular system. Circ Res 94:433–445PubMedGoogle Scholar
  45. Jaffer FA, Weissleder R (2005) Molecular imaging in the clinical arena. JAMA 293:855–862PubMedGoogle Scholar
  46. Jain KK (2004a) Role of oncoproteomics in the personalized management of cancer. Expert Rev Proteomics 1:49–55PubMedGoogle Scholar
  47. Jain KK (2004b) Applications of biochips: from diagnostics to personalized medicine. Curr Opin Drug Discov Dev 7:285–289Google Scholar
  48. Jain KK (2005a) The role of nanobiotechnology in drug discovery. DDT 10:1435–1442PubMedGoogle Scholar
  49. Jain KK (2005c) Nanotechnology-based drug delivery for cancer. Technol Cancer Res Treat 4:407–416PubMedGoogle Scholar
  50. Jain KK (2005d) Personalized medicine for cancer: from drug development into clinical practice. Expert Opin Pharmacother 6:1463–1476PubMedGoogle Scholar
  51. Jain KK (2005b) Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 4:645–650PubMedGoogle Scholar
  52. Johansson LO, Bjornerud A, Ahlstrom HK, Ladd DL, Fuji DK (2001) A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J Magn Reson Imaging 13:613–618Google Scholar
  53. Kallioniemi OP (2001) Biochip technologies in cancer research. Ann Med 33:142–147PubMedGoogle Scholar
  54. Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov A Jr (2002) Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug Chem 13:122–127PubMedGoogle Scholar
  55. Khalil IG, Hill C (2005) Systems biology for cancer. Curr Opin Oncol 17:44–48PubMedGoogle Scholar
  56. Kim J, Park S, Lee JE, Jin SM, Lee JH, Lee IS, Yand I, Kim J-S, Kim SK, Cho M-H, Hyeon T (2006) Designed fabrication of multifunctional magnetic gold nanoshells and their application to magnetic resonance imaging and photothermal therapy. Agnew Chem Int Ed 45:1–6Google Scholar
  57. Kim S, Lim YT, Soltesz EG, DeGrand AM, Lee J, Nakayama A, Parker JA, Mihaljevic T, Laurence RG, Dor DM, Cohn LH, Bawendi MG, Frangioni JV (2004) Near-infrared fluorescent type-II quantum dots for sentinel lymph node mapping. Nat Biotechnol 22:93–97PubMedGoogle Scholar
  58. Kircher MF, Allport J, Graves EE, Love V, Josephson L, Licht­man A, Weissleder R (2003) In vivo high resolution 3D imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 63:6838–6846PubMedGoogle Scholar
  59. Kitano H (2002) Systems biology: a brief overview. Science 295:1662–1664PubMedGoogle Scholar
  60. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Frederik PM, Daemen MJ, van Engelshoven JM (2003) Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107:2453–2458PubMedGoogle Scholar
  61. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich N, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The Connectivity Map: using gene expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935PubMedGoogle Scholar
  62. Langereis S, de Lussanet QG, van Genderen MH, Meijer EW, Beets-Tan RG, Griffioen AW, van Engelshoven JM, Backes WH (2006) Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed 19:133–141PubMedGoogle Scholar
  63. Lee KB, Park SJ, Mirkin CA, Smith JC, Mrksich M (2002) Protein nanoarrays generated by dip-pen nanolithography. Science 295:1702–1705PubMedGoogle Scholar
  64. Li KCP, Pandit SD, Guccione S, Bednarski MD. Molecular imaging applications in nanomedicine (2004) Biomed. Microdevices 6:113–116Google Scholar
  65. Lin B, White T, Lu W, Xie T, Utleg AG, Yan X, Yi EC, Shannon P, Khrebtukova I, Lange PH, Goodlett DR, Zhou D, Vasicek TJ, Hood L (2005) Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 65:3081–3091PubMedGoogle Scholar
  66. Loo C, Lowery A, Halas N, West J, Drezek R (2005) Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett 5:709–711PubMedGoogle Scholar
  67. Majoros IJ, Myc A, Thomas T, Mehta CB, Baker JR 92006) PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 7:572–579Google Scholar
  68. Malik N et al (2006) US patent 7005124Google Scholar
  69. Martin M (2006) Molecular biology of breast cancer Clin Transl Oncol 8:7–14 Google Scholar
  70. Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545–580PubMedGoogle Scholar
  71. McKendry R, Zhang J, Arntz Y, Strunz T, Hegner M, Lang HP, Baller MK, Certa U, Meyer E, Guntherodt J, Gerber C (2002) Multiple label-free biodetection and quantitative DNA binding assays on a nanomechanical cantilever array. Proc Natl Acad Sci USA 99:9783–9788PubMedGoogle Scholar
  72. Melosh NA, Boukai A, Diana F, Gerardot B, Badolato A, Petroff PM, Heath JR (2003) Ultrahigh density nanowire lattices and circuits. Science 300:112–115PubMedGoogle Scholar
  73. Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, Robertson JD, Abendschein DR, Lanza GM, Wickline SA (2004) Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med 51:480–486PubMedGoogle Scholar
  74. Mulder WJM, Koole R, Brandwijk RJ, Storm G, Chin PTK, Strijkers GJ, Mello Donega C, Nicolay K, Griffioen AW (2006) Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett 6:1–6PubMedGoogle Scholar
  75. Muruganandam A, Tanha J, Narang S, Stanimirovic D (2001) Selection of phage-displayed llama single-chain domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J 16:240–242PubMedGoogle Scholar
  76. Ozkan M (2004) Quantum dots and other nanoparticles: what can they offer to drug discovery? DDT 9:1065–1071PubMedGoogle Scholar
  77. Padilla De Jesus OL, Ihre HR, Gagne L, Frechet JM, Szoka FC (2002) Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem 13:453–461PubMedGoogle Scholar
  78. Pantoja R, Nagarah JM, Starace DM, Melosh NA, Blunck R, Bezanilla F, Heath JR (2004) Silicon chip-based patch clamp electrodes integrated with PDMS microfluidics. Biosens Bioelectron 20:509–517PubMedGoogle Scholar
  79. Parak WJ, Boudreau R, LeGros M, Gerion D, Zanchet D, Micheel CM, Williams SC, Alivisatos SP, Larabell C (2002) Cell motility and metastatic potential studies based on quantum dot imaging of phagokinetic tracks. Adv Mater 14:882–885Google Scholar
  80. Peano C, Severgnini M, Cifola I, DeBellis G, Battaglia C (2006) Transciptome amplification methods in gene expression profiling. Expert Rev Mol Diagn 6:465–480PubMedGoogle Scholar
  81. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103:2794–2799PubMedGoogle Scholar
  82. Revets H, De Baetselier P, Muyldermans S (2005) Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 5:111–124PubMedGoogle Scholar
  83. Rohde RD, Agnew HD, Yeo W-S, Heath JR (2006) A Non-Oxidative approach towards chemically and electrochemically biofunctionalizing Si(111). J Am Chem Soc 128:9518–9525PubMedGoogle Scholar
  84. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, van Bergen En Henegouwen PM (2007) Efficient inhibition of EGFR signaling and of tumour growth by antagonist-EGFR nanobodies. Cancer Immunol Immunother 56:303–317PubMedGoogle Scholar
  85. Rudin M, Weissleder R (2003) Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2:123–131PubMedGoogle Scholar
  86. Saerens D, Kinne J, Bosmans E, Wernery U, Muydermans S, Conrath K (2004) Single-domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate specific antigen. J Biol Chem 279:51965–51972PubMedGoogle Scholar
  87. Sahoo SK, Labhasetwar V (2003) Nanotech approaches to drug delivery and imaging. DDT 8:1112–1120PubMedGoogle Scholar
  88. Schellenberger EA, Bogdanov A, Hogemann D, Tait J, Weissleder R, Josephson L (2002) Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol Imaging 1:102–107PubMedGoogle Scholar
  89. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G, Robertson JD, Wickline SA, Lanza GM (2005) Molecular MR Imaging of Melanoma Angiogenesis with anb3-targeted paramagnetic nanoparticles. Magn Res Med 53:621–627Google Scholar
  90. Sipkins DA. Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KCP. Detection of tumor angiogenesis in vivo by anb3-targeted magnetic resonance imaging. Nat. Med. 1998 May; 4:623–626Google Scholar
  91. Sirol M, Fuster V, Badimon JJ et al (2005) Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 112:1594–1600PubMedGoogle Scholar
  92. Smith AM, Dave S, Nie S, True L, Gao X (2006) Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagn 6:231–244PubMedGoogle Scholar
  93. Sukhanova A, Venteo L, Devy M, Artemyev M, Oleinikov V, Pluot M, Nabiev I (2002) Highly stable fluorescent nanocrystals as a novel class of labels for immunohistochemical analysis of paraffin-embedded tissue sections. Lab Invest 82:1259–1261PubMedGoogle Scholar
  94. Sukhanova A, Devy M, Venteo L, Kaplan H, Artemyev M, Oleinikov V, Klinov D, Pluot M, Cohen JH, Nabiev I (2004) Biocompatible fluorescent nanocrystals for immunolabeling of membrane proteins and cells. Anal Biochem 324:60–67PubMedGoogle Scholar
  95. Sullivan DC, Ferrari M (2004) Nanotechnology and tumor imaging. Mol Imaging 3:364–369PubMedGoogle Scholar
  96. Talanov VS, Regino CA, Kobayashi H, Bernardo M, Choyke PL, Brechbiel MW (2006) Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett 6:1459–1463PubMedGoogle Scholar
  97. Thrall J (2004) Personalized medicine. Radiology 231:613–616PubMedGoogle Scholar
  98. Tripathi PK (2002) Dendrimer grafts for delivery of 5-fluorouracil. Pharmazie 57:261–264PubMedGoogle Scholar
  99. VanDelinder V, Groisman A (2006) Separation of plasma from whole human blood in a continuous cross-flow in a molded microfluidic device. Anal Chem 78:3765–3771Google Scholar
  100. Vries IJ de, Lesterhuis WJ, Barentsz JO et al (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapies. Nat Biotechnol 23:1407–1413PubMedGoogle Scholar
  101. Wagner PD, Maruvada P, Srivastava S (2004) Molecular diagnostics: a new frontier in cancer prevention. Expert Rev Mol Diagn 4:503–511PubMedGoogle Scholar
  102. Weber BL (2002) Cancer genomics. Cancer Cell 1:37–47PubMedGoogle Scholar
  103. Weissleder R (2002) Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2:11–18PubMedGoogle Scholar
  104. Weinberg R (2006) The biology of cancer. Garland, New York Google Scholar
  105. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L (2005) Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 23:1418–1423PubMedGoogle Scholar
  106. Weston AD, Hood L (2004) Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 3:179–196PubMedGoogle Scholar
  107. Winter PM, Lanza GM, Wickline SA (2003) Molecular imaging of angiogenesis in early-stage atherosclerosis with anb3-integrin-targeted nanoparticles. Circulation 108:2270–2274PubMedGoogle Scholar
  108. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, Ge N, Peale F, Bruchez MP (2003) Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 21:41–46PubMedGoogle Scholar
  109. Yu X, Song SK, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, Gaffney PJ, Wickline SA, Lanza GM (2000) High-resolution MRI characterization of human thrombus using a novel fibrin-targeted nanoparticle contrast agent. Magn Reson Med 44:867–872PubMedGoogle Scholar
  110. Zimmermann M, Delamarche E, Wolf M, Hunziker P (2005) Modeling and optimization of high-sensitivity, low-volume microfluidic-based surface immunoassays. Biomed Microdevices 7:99–110PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Michelle S. Bradbury
    • 1
  • Hedvig Hricak
    • 2
  • James R. Heath
    • 3
  1. 1.Department of RadiologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of RadiologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Divsion of Chemistry and Chemical Engineering, California Insitute of TechnologyPasadenaUSA

Personalised recommendations